Commentary

Is Red Meat Healthy? Multiverse Analysis Has Lessons Beyond Meat


 

Observational studies on red meat consumption and lifespan are prime examples of attempts to find signal in a sea of noise.

Randomized controlled trials are the best way to sort cause from mere correlation. But these are not possible in most matters of food consumption. So, we look back and observe groups with different exposures.

My most frequent complaint about these nonrandom comparison studies has been the chance that the two groups differ in important ways, and it’s these differences — not the food in question — that account for the disparate outcomes.

But selection biases are only one issue. There is also the matter of analytic flexibility. Observational studies are born from large databases. Researchers have many choices in how to analyze all these data.

A few years ago, Brian Nosek, PhD, and colleagues elegantly showed that analytic choices can affect results. His Many Analysts, One Data Set study had little uptake in the medical community, perhaps because he studied a social science question.

Multiple Ways to Slice the Data

Recently, a group from McMaster University, led by Dena Zeraatkar, PhD, has confirmed the analytic choices problem, using the question of red meat consumption and mortality.

Their idea was simple: Because there are many plausible and defensible ways to analyze a dataset, we should not choose one method; rather, we should choose thousands, combine the results, and see where the truth lies.

You might wonder how there could be thousands of ways to analyze a dataset. I surely did.

The answer stems from the choices that researchers face. For instance, there is the selection of eligible participants, the choice of analytic model (logistic, Poisson, etc.), and covariates for which to adjust. Think exponents when combining possible choices.

Dr. Zeraatkar and colleagues are research methodologists, so, sadly, they are comfortable with the clunky name of this approach: specification curve analysis. Don’t be deterred. It means that they analyze the data in thousands of ways using computers. Each way is a specification. In the end, the specifications give rise to a curve of hazard ratios for red meat and mortality. Another name for this approach is multiverse analysis.

For their paper in the Journal of Clinical Epidemiology, aptly named “Grilling the Data,” they didn’t just conjure up the many analytic ways to study the red meat–mortality question. Instead, they used a published systematic review of 15 studies on unprocessed red meat and early mortality. The studies included in this review reported 70 unique ways to analyze the association.

Is Red Meat Good or Bad?

Their first finding was that this analysis yielded widely disparate effect estimates, from 0.63 (reduced risk for early death) to 2.31 (a higher risk). The median hazard ratio was 1.14 with an interquartile range (IQR) of 1.02-1.23. One might conclude from this that eating red meat is associated with a slightly higher risk for early mortality.

Their second step was to calculate how many ways (specifications) there were to analyze the data by totaling all possible combinations of choices in the 70 ways found in the systematic review.

They calculated a total of 10 quadrillion possible unique analyses. A quadrillion is 1 with 15 zeros. Computing power cannot handle that amount of analyses yet. So, they generated 20 random unique combinations of covariates, which narrowed the number of analyses to about 1400. About 200 of these were excluded due to implausibly wide confidence intervals.

Voilà. They now had about 1200 different ways to analyze a dataset; they chose an NHANES longitudinal cohort study from 2007-2014. They deemed each of the more than 1200 approaches plausible because they were derived from peer-reviewed papers written by experts in epidemiology.

Pages

Recommended Reading

CRC Screening in Primary Care: The Blood Test Option
MDedge Hematology and Oncology
Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
MDedge Hematology and Oncology
Routine Breast Cancer Screening Should Start at Age 40: USPSTF
MDedge Hematology and Oncology
Cervical Cancer Screening: US Clinicians Unclear About Best Practices
MDedge Hematology and Oncology
The Long, Controversial Search for a ‘Cancer Microbiome’
MDedge Hematology and Oncology
MicroRNAs May Predict Pancreatic Cancer Risk Years Before Diagnosis
MDedge Hematology and Oncology
Do Health-Related Social Needs Raise Mortality Risk in Cancer Survivors?
MDedge Hematology and Oncology
Negative Colonoscopy? 15-Year Screening Interval May Be Safe
MDedge Hematology and Oncology
Can a Risk Score Predict Kidney Injury After Cisplatin?
MDedge Hematology and Oncology
New mRNA Vaccines in Development for Cancer and Infections
MDedge Hematology and Oncology